A protein found in human and animal blood.
A protein released by the immune system to fight foreign substances that enter the body.
Bleeding into muscles, organs and joint spaces.
Carefully controlled studies that test the safety and efficacy of medications.
Normal clotting process that arrests bleeding.
A blood protein involved in the normal clotting process (coagulation); also a shortening of the term ‘factor replacement therapy’, i.e. XYNTHA.
A clotting factor protein needed for coagulation; low in people with haemophilia A.
A clotting factor protein needed for coagulation; low in people with haemophilia B.
Passed on from parents to children through genes.
Administration of factor replacement therapy.
An antibody that neutralises a coagulation factor and interferes with its function, leading to treatment complications.
Additional step in the XYNTHA purification process involving a tiny 35 nanometre filter.
Using factor replacement in response to a bleeding episode or injury.
Devices implanted under the skin to improve vein access; often used in young children.
Using factor replacement as a preventative treatment.
Man-made molecule in the XYNTHA purification process.
Deficiency in the clotting protein called von Willebrand factor.